Related Experiment Video
Updated: Feb 2, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
MukoHelp: A self-help manual for patients with cystic fibrosis-Results from a randomized controlled trial
Carina von Stackelberg1, Steffen Moritz1, Tana Gabbert1
1Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Background:
There is a high prevalence of anxiety and depression in patients with cystic fibrosis (CF) but only a few interventions tailored to their needs. To date, no effective CF-specific self-help interventions exist, even though such interventions have the potential to overcome treatment barriers. This randomized controlled trial evaluated the acceptance and efficacy of MukoHelp, the first unguided self-help intervention in patients with self-reported CF.
Methods:
Participants (N = 82) were randomized to either the MukoHelp group (n = 41) or a waitlist control group (n = 41). Patients were assessed before (baseline), after the six-week intervention period (post), and three months after post (follow-up). Assessments included acceptability (Client Satisfaction Questionnaire; CSQ), efficacy (e.g., anxiety; Generalized Anxiety Disorder-7 Scale; GAD-7), and adherence.
Results:
MukoHelp received mixed acceptability with a high acceptance according to the CSQ (75.7%), but adherence was low, indicating low acceptability. The intervention did not lead to significant improvements in symptoms of anxiety compared to waitlist controls (p = .645, ηp2 = 0.005). Exploratory analyses suggest that low adherence impacted efficacy as the item "I apply what I have learned in the MukoHelp chapters in my everyday life" was negatively correlated at a moderate effect size with the GAD-7 baseline-post difference score (r = -0.500, p = .035).
Conclusions:
While some participants reported satisfaction, overall engagement and adherence were low, and no symptom improvements were observed. This suggests that future versions of MukoHelp should focus on increasing sustained usage-potentially through added guidance or supportive elements-to enhance feasibility and therapeutic impact.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...
Random Error

